Anavex Receives FDA Clearance for Blarcamesine IND Application
The FDA cleared Anavex's investigational new drug application for blarcamesine in Fragile X syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Anavex Receives FDA Clearance for Blarcamesine Fragile X Study
Anavex said its IND application for blarcamesine in Fragile X syndrome has received FDA clearance. A Phase 2a study will evaluate safety, tolerability and pharmacokinetics in adult males.